A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Rivaroxaban
Test Code90981
CPT Codes
80299
Preferred Specimen
1 mL frozen plasma collected in a 3.2% sodium citrate (light blue-top) tube
Patient Preparation
Collect samples 2-4 hours post dose (peak)
Minimum Volume
0.5 mL
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 28 days
Refrigerated: Unacceptable
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Thawed plasma
Methodology
Chromogenic
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
A.M. Sets up 3 days a week.
Report Available
Reports in 1 day.
Clinical Significance
Rivaroxaban is an oral factor Xa inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also indicated for the treatment, prophylaxis, or the reduction in the risk of reoccurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). Rivaroxaban does not need to be monitored routinely, however, exceptions may include determination of failure of therapy vs. poor compliance, or potential dose adjustment required for renal or hepatic dysfunction.